Thomas C Marbury (Thomas Marbury)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Advanced Non Small Cell Lung Cancer

Chronic Lymphocytic Leukemia

Top Venues

Clinical and translational science

Communications medicine

Pharmacotherapy

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Norah G Verbout, Christina U Lorentz, Brandon D Markway, Michael Wallisch, Thomas C Marbury, Enrico Di Cera, Joseph J Shatzel, András Gruber, Erik I Tucker
Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial. Communications medicine 4 (1) (2024)
Rajinder Bhardwaj, Mary K Donohue, Jennifer Madonia, Beth A Morris, Thomas C Marbury, Kyle T Matschke, Robert Croop, Richard Bertz, Jing Liu
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment. Clinical and translational science 17 (7) (2024)
Shawn Flanagan, Voon Ong, Thomas C Marbury, Alena Jandourek, Ronak G Gandhi, Taylor Sandison
Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Pharmacotherapy (2024)
Norah G Verbout, Christina U Lorentz, Brandon D Markway, Michael Wallisch, Thomas C Marbury, Enrico Di Cera, Joseph J Shatzel, András Gruber, Erik I Tucker
Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial. Communications medicine 4 (1) (2024)
Norah G Verbout, Christina U Lorentz, Brandon D Markway, Michael Wallisch, Thomas C Marbury, Enrico Di Cera, Joseph J Shatzel, András Gruber, Erik I Tucker
Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial. Communications medicine 4 (1) (2024)
Rajinder Bhardwaj, Mary K Donohue, Jennifer Madonia, Beth A Morris, Thomas C Marbury, Kyle T Matschke, Robert Croop, Richard Bertz, Jing Liu
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment. Clinical and translational science 17 (7) (2024)
Shawn Flanagan, Voon Ong, Thomas C Marbury, Alena Jandourek, Ronak G Gandhi, Taylor Sandison
Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Pharmacotherapy 44 (6) (2024)
Norah G Verbout, Christina U Lorentz, Brandon D Markway, Michael Wallisch, Thomas C Marbury, Enrico Di Cera, Joseph J Shatzel, András Gruber, Erik I Tucker
Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial. Communications medicine 4 (1) (2024)
Rajinder Bhardwaj, Mary K Donohue, Jennifer Madonia, Beth A Morris, Thomas C Marbury, Kyle T Matschke, Robert Croop, Richard Bertz, Jing Liu
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment. Clinical and translational science 17 (7) (2024)
Shawn Flanagan, Voon Ong, Thomas C Marbury, Alena Jandourek, Ronak G Gandhi, Taylor Sandison
Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Pharmacotherapy 44 (6) (2024)
Ling Gao, Ikuo Yamamiya, Mark Pinti, Juan Carlos Rondon, Thomas C Marbury, Gareth Tomlinson, Lukas Makris, Nanae Hangai, Volker Wacheck
A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib. Clinical and translational science (2023)
Behnam Noorani, Rajeev M Menon, Xin Chen, Kennan C Marsh, Weize Huang, Shelly Gupta, Edyta Dobkowska, Thomas C Marbury, Ahmed Hamed Salem
Venetoclax Pharmacokinetics in Participants with End-stage Renal Disease Undergoing Hemodialysis. British journal of clinical pharmacology (2023)
Michael J Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C Marbury, Karthik Venkatakrishnan, Neeraj Gupta
Brigatinib pharmacokinetics in patients with chronic hepatic impairment. Investigational new drugs (2023)
Neeraj Gupta, Michael J Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C Marbury, Karthik Venkatakrishnan
Effect of severe renal impairment on the pharmacokinetics of brigatinib. Investigational new drugs 39 (5) (2021)